News

Article

Lonza Announces Agreement with Alexion

The addition of a new manufacturing line at Lonza’s Portsmouth, NH site enables Alexion to add dedicated product supply for 10 years.

Lonza Group announced on July 2 a long-term product supply agreement with Alexion under which Lonza will construct and launch a new suite dedicated to Alexion manufacturing at Lonza’s Portsmouth, NH site. Lonza reports the manufacturing line will be operational by the end of 2017

The agreement, and expansion of an existing manufacturing agreement, will supplement existing production of Alexion products at multiple Lonza facilities. Lonza will own and operate the suite at the Portsmouth site.

The expansion of the existing site will provide increased access to Lonza’s biological manufacturing and regulatory expertise, global workforce and customer service. Lonza has more than two decades of manufacturing experience with mammalian biotherapeutics.

Source: Lonza

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content